On the other hand, the combination therapy can reduce the IL-6 expression by 69% relative to the TZB treatment (TZB+ATV−), showing strong neutralizing effect of ATV on CRCC in the TZB-driven anti-cancer therapy. The gene discussed is IL6; the disease is chromophobe renal cell carcinoma.